Your browser is no longer supported. Please, upgrade your browser.
CGTX [NASD]
Cognition Therapeutics, Inc.
Index- P/E- EPS (ttm)-20.30 Insider Own27.90% Shs Outstand22.82M Perf Week-45.90%
Market Cap79.87M Forward P/E- EPS next Y-1.17 Insider Trans0.05% Shs Float13.39M Perf Month-36.01%
Income- PEG- EPS next Q-0.20 Inst Own0.30% Short Float0.17% Perf Quarter-71.22%
Sales- P/S- EPS this Y-37.80% Inst Trans- Short Ratio0.29 Perf Half Y-
Book/sh-140.80 P/B- EPS next Y28.70% ROA- Target Price24.50 Perf Year-
Cash/sh0.36 P/C9.62 EPS next 5Y- ROE- 52W Range3.99 - 13.80 Perf YTD-44.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-74.64% Beta-
Dividend %- Quick Ratio2.30 Sales past 5Y- Gross Margin- 52W Low-12.28% ATR0.78
Employees15 Current Ratio2.30 Sales Q/Q- Oper. Margin- RSI (14)26.81 Volatility18.78% 12.91%
OptionableNo Debt/Eq- EPS Q/Q-32.70% Profit Margin- Rel Volume1.83 Prev Close4.14
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume80.03K Price3.50
Recom1.50 SMA20-41.88% SMA50-54.61% SMA200-61.43% Volume146,479 Change-15.46%
Nov-03-21Initiated Oppenheimer Outperform $22
Nov-03-21Initiated B. Riley Securities Buy $27
Jan-10-22 07:30AM  
Jan-08-22 07:01AM  
Jan-04-22 07:30AM  
Dec-21-21 07:30AM  
Nov-30-21 07:30AM  
Nov-18-21 08:00AM  
Nov-15-21 07:30AM  
Nov-03-21 08:00AM  
Nov-02-21 06:00AM  
Oct-18-21 10:59AM  
04:37AM  
Oct-15-21 10:26AM  
Oct-12-21 11:23AM  
Oct-08-21 05:50PM  
07:42AM  
07:30AM  
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer's disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wallace PeggyDirectorOct 13Buy12.003,00036,0003,000Oct 25 08:18 PM